Prolonged administration of antithymocyte serum in mice. II. Histopathological investigation.
D000230:Adenocarcinoma / Q000209:etiology; D008949:Adenoma, Pleomorphic / Q000209:etiology; D000686:Amyloidosis / Q000139:chemically induced; D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology*; D002277:Carcinoma; D005260:Female; D007413:Intestinal Mucosa / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007680:Kidney Neoplasms / Q000209:etiology; D008099:Liver / Q000473:pathology; D008198:Lymph Nodes / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects; D008221:Lymphoid Tissue / Q000187:drug effects; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology; D008297:Male; D008321:Mammary Glands, Animal; D051379:Mice; D009369:Neoplasms / Q000209:etiology; D009393:Nephritis / Q000139:chemically induced; D012516:Osteosarcoma / Q000209:etiology; D010950:Plasma Cells; D011120:Polyomavirus; D011817:Rabbits; D016038:Skin Transplantation; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D013950:Thymus Gland / Q000187:drug effects / Q000276:immunology*
D000961:Antilymphocyte Serum